Stocks · News reference
Martin Shkreli shorts Hims & Hers stock, calling its peptides fake medicine.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower costs translate into meaningful savings as early as 12 months into treatment. This is the first study of its kind in
Read original at benzingaTruist Securities analyst Jailendra Singh maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $27 to $32.
Read original at benzingaBarclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.
Read original at benzingaHims & Hers CEO Andrew Dudum defends the firm against an FTC lawsuit, discusses dropping GLP-1 drug prices and reveals in-house AI plans.
Read original at benzinga